THE preliminary results of infectious complications in orthotopic liver transplantation IOLT) using FK 506 as a primary immunosuppressive agent were encouraging. I This early experience. however. was limited to only 20 patients who were followed for a short period of time. We have now extended our observations to 110 consecutive adult liver transplant recipients of first livers enrolled in the ...

Severe graft-versus-host disease was induced by transplantation of ACI rat bone marrow and spleen cells into irradiated Lewis rat recipients. Treatment with FK 506 or cyclosporine A (CsA) was started after clinical and histologic evidence of acute GVHD was present. A 14-day course of FK 506 at 1.0 mg/kg/day could rescue 100% of the animals suffering from GVHD. In contrast only one half of the a...

FK 506, a novel immunosuppressive agent, was first used to reverse rejection in liver recipients who had failed to respond to conventional therapy.' The successful outcome of the initial study has led to clinical trials of FK 506 as the primary immunosuppressive agent for liver allografts and other organ transplants. 2-4 Ongoing studies include dosage protocols for optimal immunosuppression wit...

THE USE of cyclosporine (CyA) has greatly impacted the success of liver transplantation. FK 506 is a newly described immunosuppressive agent, with mechanisms of action similar to those of Cy A, but more potent on a weight-ta-weight basis. Pilot studies of FK 506 in primary liver transplantation have shown encouraging results. 1 A randomized trial using FK 506 with low-dose steroids (LDS) was co...

The BB rat is the experimental analogue of human juvenile diabetes mellitus. From 30 through 120 days after birth, 59 BB rats were treated with water (n = 20), or FK 506 in daily intragastric doses of 1 mg/kg (n = 19) or 2 mg/kg (n = 20). Diabetes developed in 75%, 15%, and 0% of the three groups. Animals protected from diabetes by FK 506, and killed in the nondiabetic state at 120 days had nor...

The immunosuppressant FK506 binds Plasmodium falciparum FK-506 binding protein 35 (PfFKBP35) and shows anti-malarial activity. To understand molecular mechanism of the drug on the parasite, we have done NMR studies. Here, we report the assignment of FK506-binding domain of PfFKBP35.

I N ADDITION to immunosuppression. complex and for the most part similar metabolic effects are caused by cyclosporine (CyA) and FK 506. even though these drugs are chemically unrelated and have different cytosolic binding sites (called immunophilins) (Table I). One of the striking nonimmunological effects of Cy A and FK S06 is hepatocyte proliferation. which can be demonstrated in the in vivo m...

FK 506 was tested in unrelated baboons submitted to renal transplantation and bilateral native nephrectomy. Untreated baboons died after 9.2 +/- 4.0 SD days. When FK 506 was given orally for 90 days, survival with the optimum dose was 74.6 +/- 28.9 days; this allowed maximum credit for each individual animal of 90 days. A 3-day course of intramuscular FK 506 started on postoperative day 4 allow...